Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million

Reuters2026/08/05 22:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cytek posted Q2 2026 revenue of $48.1 million, up 6% year over year.
GAAP net loss widened to $12.2 million; GAAP operating loss widened to $11.4 million.
GAAP gross margin rose to 59% from 52%, lifting gross profit 19% to $28.3 million.
Non-GAAP adjusted EBITDA turned to a loss of $1.5 million from a profit of $1.3 million.
Raised FY 2026 revenue guidance to $207 million-$212 million; installed base reached 3,933 instruments after adding 142 units in Q2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million

You may also like

Crypto prices